Angle raises £12.2 million to purchase biopsy assets

Angle Plc has raised £12.2 million, before expenses, to finance the purchase of assets from Canada-based Axela Inc that will broaden its liquid biopsy capabilities enabling it to both harvest circulating tumour cells from patients and analyse them for gene expression.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom